Allergan had a rough year in 2017, dropping by close to $80 a share from February 2017 to this month. However, with the financials it has just posted, it may be able to shore up belief that the company has the ability to stop the rot.
One indicator of where the company hopes it can achieve growth was on the announcement of results from its oral CGRP inhibitor, ubrogepant.
